Table of Contents
1. Executive Summary
2. Market Background and Classifications
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2014 to 2025
3.1: Macroeconomic Trends and Forecast
3.2: Global Large Molecule Bioanalytical Testing Service Market Trends and Forecast
3.3: Global Large Molecule Bioanalytical Testing Service Market by Test Type
3.3.1: ADME (Absorption, Distribution, Metabolism and Excretion)
3.3.2: PK (Pyruvate Kinase)
3.3.3: PD (Partial Discharge)
3.3.4: Bioavailability
3.3.5: Bioequivalence
3.3.6: Other Test
3.4: Global Large Molecule Bioanalytical Testing Service Market by Type
3.4.1: Pharmacokinetics
3.4.2: Anti Drug Antibody (ADA)
3.4.3: Others
3.5: Global Large Molecule Bioanalytical Testing Service Market by Phase
3.5.1: Preclinical
3.5.2: With Antibody
3.5.3: Without Antibody
3.5.4: Clinical
3.6: Global Large Molecule Bioanalytical Testing Service Market by Therapeutic Area
3.6.1: Oncology
3.6.2: Infectious Diseases
3.6.3: Cardiology
3.6.4: Neurology
3.6.5: Others
3.7: Global Large Molecule Bioanalytical Testing Service Market by End User
3.7.1: Small and Mid Size Enterprise (SMEs)
3.7.2: Large Firms
4. Market Trends and Forecast Analysis by Region
4.1: Global Large Molecule Bioanalytical Testing Service Market by Region
4.2: North American Large Molecule Bioanalytical Testing Service Market
4.2.1: Market by Test Type: ADME (Absorption, Distribution, Metabolism and Excretion), PK (Pyruvate Kinase), PD (Partial Discharge), Bioavailability, Bioequivalence, and Other Test
4.2.2: Market by Type: Pharmacokinetics, Anti Drug Antibody (ADA), and Others
4.2.3: Market by Phase: Preclinical,With Antibody, Without Antibody (ELISA Based Assay), and Clinical
4.2.4: Market by Therapeutic Area: Oncology, Infectious Diseases, Cardiology, Neurology, and Others
4.2.5: Market by End User: Small and Mid Size Enterprise (SMEs) and Large Firms
4.2.6: The United States Large Molecule Bioanalytical Testing Service Market
4.2.7:The Canadian Large Molecule Bioanalytical Testing Service Market
4.2.8: The Mexican Large Molecule Bioanalytical Testing Service Market
4.3: European Large Molecule Bioanalytical Testing Service Market
4.3.1: Market by Test Type: ADME (Absorption, Distribution, Metabolism and Excretion), PK (Pyruvate Kinase), PD (Partial Discharge), Bioavailability, Bioequivalence, and Other Test
4.3.2: Market by Type: Pharmacokinetics, Anti Drug Antibody (ADA), and Others
4.3.3: Market by Phase: Preclinical,With Antibody, Without Antibody (ELISA Based Assay), and Clinical
4.3.4: Market by Therapeutic Area: Oncology, Infectious Diseases, Cardiology, Neurology, and Others
4.3.5: Market by End User: Small and Mid Size Enterprise (SMEs) and Large Firms
4.3.6: The Large Molecule Bioanalytical Testing Service Market of United Kingdom
4.3.7: The German Large Molecule Bioanalytical Testing Service Market
4.3.8: The French Large Molecule Bioanalytical Testing Service Market
4.4: APAC Large Molecule Bioanalytical Testing Service Market
4.4.1: Market by Test Type: ADME (Absorption, Distribution, Metabolism and Excretion), PK (Pyruvate Kinase), PD (Partial Discharge), Bioavailability, Bioequivalence, and Other Test
4.4.2: Market by Type: Pharmacokinetics, Anti Drug Antibody (ADA), and Others
4.4.3: Market by Phase: Preclinical,With Antibody, Without Antibody (ELISA Based Assay), and Clinical
4.4.4: Market by Therapeutic Area: Oncology, Infectious Diseases, Cardiology, Neurology, and Others
4.4.5: Market by End User: Small and Mid Size Enterprise (SMEs) and Large Firms
4.4.6: The Chinese Large Molecule Bioanalytical Testing Service Market
4.4.7: The Indian Large Molecule Bioanalytical Testing Service Market
4.4.8: The Japanese Large Molecule Bioanalytical Testing Service Market
4.5: ROW Large Molecule Bioanalytical Testing Service Market
4.5.1: Market by Test Type: ADME (Absorption, Distribution, Metabolism and Excretion), PK (Pyruvate Kinase), PD (Partial Discharge), Bioavailability, Bioequivalence, and Other Test
4.5.2:Market by Type: Pharmacokinetics, Anti Drug Antibody (ADA), and Others
4.5.3: Market by Phase: Preclinical,With Antibody, Without Antibody (ELISA Based Assay), and Clinical
4.5.4: Market by Therapeutic Area: Oncology, Infectious Diseases, Cardiology, Neurology, and Others
4.5.5: Market by End User: Small and Mid Size Enterprise (SMEs) and Large Firms
4.5.6: Brazilian Large Molecule Bioanalytical Testing Service Market
5. Competitor Analysis
5.1: Market Share Analysis
5.2: Product Portfolio Analysis
5.3: Operational Integration
5.4: Geographical Reach
5.5: Porter’s Five Forces Analysis
6. Cost Structure Analysis
6.1: Cost of Goods Sold
6.2: SG&A
6.3: EBITDA Margin
7. Growth Opportunities and Strategic Analysis
7.1: Growth Opportunity Analysis
7.1.1: Growth Opportunities for the Global Large Molecule Bioanalytical Testing Service Market by Test Type
7.1.2: Growth Opportunities for the Global Large Molecule Bioanalytical Testing Service Market by Type
7.1.3: Growth Opportunities for the Global Large Molecule Bioanalytical Testing Service Market by Phase
7.1.4: Growth Opportunities for the Global Large Molecule Bioanalytical Testing Service Market by Therapeutic Area
7.1.5: Growth Opportunities for the Global Large Molecule Bioanalytical Testing Service Market by End User
7.1.6: Growth Opportunities for the Global Large Molecule Bioanalytical Testing Service Market by Region
7.2: Emerging Trends in the Global Large Molecule Bioanalytical Testing Service Market
7.3: Strategic Analysis
7.3.1: New Product Development
7.3.2: Capacity Expansion of the Global Large Molecule Bioanalytical Testing Service Market
7.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Large Molecule Bioanalytical Testing Service Market
7.3.4: Certification and Licensing
8. Company Profiles of Leading Players
8.1: Covance, Inc.
8.2: IQVIA
8.3: Syneos Health
8.4: SGS SA
8.5: Toxikon
8.6: Intertek Group plc
8.7: Pace Analytical Services LLC
8.8: Charles River LaboratoryInternational
8.9: ICON Plc
8.10: PPD, Inc.